Intercept's OCA Data Bolster NASH Efficacy, But Pruritus Worries Worsen

11 Apr 2019

Analysts call Intercept sell-off overblown in wake of EASL presentation of fuller Phase III data for OCA in NASH. But while depth is added to efficacy argument, pruritus concerns possibly worsen.

A more comprehensive look at Intercept Pharmaceuticals Inc.’s Phase III REGENERATE study of obeticholic acid (OCA) in non-alcoholic steatohepatitis (NASH) seemed to bolster the drug’s efficacy case, but investors drove the company’s stock price down April 11, perhaps due to increasing concerns about discontinuation rates seen in the study due to pruritus.

Intercept presented supportive data from REGENERATE at the European Association for the Study of the Liver (EASL) meeting April 11 in Vienna, revealing that more patients on the higher dose

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

07 May 2025

• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

06 May 2025

• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.